SYNERGISTIC ANTICANDIDAL AND ANTIBIOFILM ACTIVITY OF MORINGA OLEIFERA METHANOLIC EXTRACT IN COMBINATION WITH FLUCONAZOLE AGAINST CANDIDA GLABRATA

Candida glabrata is an opportunistic fungal pathogen associated with increasing antifungal resistance and biofilm-mediated persistence, limiting the effectiveness of conventional therapies. The present study investigated the anticandidal and antibiofilm activities of selected medicinal plant extracts against C. glabrata, with particular emphasis on the methanolic extract of Moringa oleifera, individually and in combination with fluconazole. Following isolation and physiological characterization of the fungal isolate, antifungal activity was evaluated using agar well diffusion, broth microdilution, minimum inhibitory concentration (MIC), biofilm inhibition and eradication assays, MTT cell viability assay, and growth kinetics. Phytochemical characterization was performed using qualitative screening, thin-layer chromatography, column chromatography, and SDS–PAGE analysis. Among the tested plant extracts, M. oleifera exhibited the strongest anticandidal activity. Combination treatment with M. oleifera and fluconazole produced enhanced antifungal efficacy, extending inhibitory activity to higher dilutions in the MIC assay and achieving greater biofilm eradication (36%), antibiofilm inhibition (45%), and reduction in fungal cell viability (43%) than either treatment alone. Time-kill and growth kinetics studies further demonstrated sustained inhibition of fungal growth following combination treatment. Phytochemical analyses confirmed the presence of phenolics, flavonoids, alkaloids, terpenoids, glycosides, and other bioactive constituents that may contribute to the observed biological activity. Statistical analysis of triplicate experiments confirmed the reproducibility of the experimental findings (P < 0.05). Collectively, these results demonstrate that M. oleifera methanolic extract potentiates the antifungal activity of fluconazole and represents a promising natural adjunct for the management of biofilm-associated C. glabrata infections.

• Abbas, H. H., & Atiyah, M. M. (2018). Anti-fungal activities of aqueous and alcoholic leaf extracts of Moringa oleifera Lam. on Candida albicans isolated from diabetic foot infections. Journal of Global Pharma Technology, 10(5): 123–131.
• Adnan, M., Umer, A., Ahmad, I., Hayat, K., & Shakeel, S. N. (2017). In vitro evaluation of biological activities of citrus leaf extracts. Sains Malaysiana, 46(8): 1345–1353.
• Alzohairy, M. A. (2016). Therapeutics role of Azadirachta indica (Neem) and their active constituents in disease prevention and treatment. Evidence-Based Complementary and Alternative Medicine, 2016; 7382506. https://doi.org/10.1155/2016/7382506
• Baral, P. K., Afroz, F., Begum, N., Rony, S. R., Sharmin, S., Moni, F., Akhter, S., Sultana, S., & Sohrab, M. H. (2018). Exploration of endophytic fungi and their bioactive potential isolated from the medicinal plant Adhatoda vasica. Research Journal of Pharmacognosy, 11(1): 9–18.
• Ben-Ami, R., Zimmerman, O., Finn, T., Amit, S., Novikov, A., Wertheimer, N., Lurie-Weinberger, M., & Berman, J. (2016). Heteroresistance to fluconazole is a continuously distributed phenotype among Candida glabrata clinical strains associated with in vivo persistence. mBio, 7(5): e00655-16. https://doi.org/10.1128/mBio.00655-16
• Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004). Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrobial Agents and Chemotherapy, 48(5): 1773–1777. https://doi.org/10.1128/AAC.48.5.1773-1777.2004
• Brass, C., Galgiani, J. N., Blaschke, T. F., Defelice, R., O’Reilly, R. A., & Stevens, D. A. (1982). Disposition of ketoconazole, an oral antifungal, in humans. Antimicrobial Agents and Chemotherapy, 21(1): 151–158. https://doi.org/10.1128/AAC.21.1.151
• Clinical and Laboratory Standards Institute. (2008). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard – Third edition (M27-A3). Clinical and Laboratory Standards Institute.
• Costa, C., Ribeiro, J., Miranda, I. M., Silva-Dias, A., Cavalheiro, M., Costa-de-Oliveira, S., Rodrigues, A. G., & Teixeira, M. C. (2016). Clotrimazole drug resistance in Candida glabrata clinical isolates correlates with increased expression of the drug:H⁺ antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2. Frontiers in Microbiology, 7: 526. https://doi.org/10.3389/fmicb.2016.00526
• Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014). Drug-resistant Candida glabrata infection in cancer patients. Emerging Infectious Diseases, 20(11): 1949–1952. https://doi.org/10.3201/eid2011.140685
• Fothergill, A. W. (2006). Miconazole: a historical perspective. Expert Review of Anti-infective Therapy, 4(2): 171–175. https://doi.org/10.1586/14787210.4.2.171
• Frej-Mądrzak, M., Golec, S., Włodarczyk, K., Teryks-Wołyniec, D., Jama-Kmiecik, A., Sarowska, J., & Choroszy-Król, I. (2021). Susceptibility to clotrimazole of Candida spp. isolated from the genitourinary system—A single center study. Pathogens, 10(5): 595. https://doi.org/10.3390/pathogens10050595
• Gani, B. A., Soraya, C., Sugiaman, V. K., & Pranata, N. (2023). Fungistatic effect of Moringa oleifera Lam. on the metabolism changes of Candida albicans. Journal of Pharmacy & Pharmacognosy Research, 11(1): 179–188.
• Gonçalves, B., Azevedo, N., Osório, H., Henriques, M., & Silva, S. (2021). Revealing Candida glabrata biofilm matrix proteome: global characterization and pH response. Biochemical Journal, 478(4): 961–974. https://doi.org/10.1042/BCJ20200955
• Gupta, P., Gupta, S., Sharma, M., Kumar, N., & Pruthi, V. (2018). Effectiveness of phytoactive molecules on transcriptional expression, biofilm matrix, and cell wall components of Candida glabrata and its clinical isolates. ACS Omega, 3(10): 14201–14211. https://doi.org/10.1021/acsomega.8b01856
• Hitchcock, C. A., Pye, G. W., Troke, P. F., Johnson, E. M., & Warnock, D. W. (1993). Fluconazole resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy, 37(9): 1962–1965. https://doi.org/10.1128/AAC.37.9.1962
• Indrastiti, R. K., Rahmayanti, F., & Kurnia, D. (2025). Antifungal activities of Moringa oleifera Lam. and its defense mechanism against Candida albicans: A literature review. AIP Conference Proceedings, 3312(1): 020003. https://doi.org/10.1063/5.0251736